ND0801
DrugConfidential
NCT Number: NCT01174355
A multicenter, open label, escalating dose study to assess the tolerability and the safety and to explore the efficacy and the pharmacokinetics of ND0801 in adult patients with attention deficit/hyperactivity disorder (ADHD).
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1 / Phase 2
Rambam Hospital, Haifa, Israel
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Confidential
Time frame: 1 week
Safety and tolerability of ND0801 will be based on adverse events reporting by the subjects during the study.
NeuroDerm Ltd.
Industry
A Multicenter, Open Label, Escalating Dose Study to Assess the Tolerability and the Safety and to Explore the Efficacy and the Pharmacokinetics of ND0801 in Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05935254
Attention Deficit Disorder with Hyperactivity, Attention Deficit and Disruptive Behavior Disorders
Aydin, Turkey (Türkiye)
View Trial DetailsNCT07731893
Attention Deficit Disorder with Hyperactivity, Attention Deficit and Disruptive Behavior Disorders
Ankara, Turkey (Türkiye)
View Trial DetailsNCT06626750
ADHD, Attention Deficit Disorder with Hyperactivity
Miami, Florida, United States
View Trial DetailsNCT04082234
ADHD, Attention Deficit Disorder with Hyperactivity
Philadelphia, Pennsylvania, United States
View Trial Details